Abstract
Reply letter to the commentary on "Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study".
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have